Mizuho Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $195.00

Axsome Therapeutics (NASDAQ:AXSM) had its price objective upped by Mizuho from $137.00 to $195.00 in a research note published on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

AXSM has been the topic of several other reports. Leerink Partners upped their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Monday. Truist Financial upped their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a report on Monday, February 3rd. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Robert W. Baird upped their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.80.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $132.20 on Tuesday. The business has a fifty day moving average of $95.28 and a 200 day moving average of $92.07. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $134.19. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm has a market capitalization of $6.41 billion, a price-to-earnings ratio of -20.25 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The firm had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. During the same quarter in the previous year, the company posted ($1.32) earnings per share. As a group, research analysts expect that Axsome Therapeutics will post -4.7 earnings per share for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after buying an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC purchased a new position in Axsome Therapeutics in the fourth quarter worth approximately $2,599,000. PDT Partners LLC acquired a new stake in Axsome Therapeutics during the third quarter worth $1,052,000. Pallas Capital Advisors LLC purchased a new stake in Axsome Therapeutics in the fourth quarter valued at $2,237,000. Finally, Captrust Financial Advisors acquired a new position in shares of Axsome Therapeutics in the 3rd quarter valued at $514,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.